It is almost six months since novel Coronavirus disease 2019 (COVID-19) started as a local outbreak in Wuhan, China(1) For hematologists and patients suffering from hematological disorders, the COVID-19 pandemic has brought challenges with regards to the diagnosis, treatment, follow-up, office visits, and so on. (2,3) We hereby discuss the current challenges for management of immune thrombocytopenia (ITP) during COVID-19 pandemic, based on our practical experience and interim expert recommendations suggested by the hematology societies. This article is protected by copyright. All rights reserved.